Latest Conference Articles

Novel oral anticoagulants have made treatment of many patients considerably easier over the past few years. Finding ways to apply that to veterans can help a patient population deserving of high quality health care.

Much like civilians, military veterans have trouble maintaining safe levels with warfarin treatment.

Asked to assume equal cost-effectiveness, the patients were given eight facets of treatment and asked to rank them between 1 and 8, with 1 being the most important to them and 8 being the least.

Among a large sample of Veterans Affairs health care patients with peripheral artery disease, researchers found African Americans were 43% more likely to lose a limb to amputation--and it is likely not because of socioeconomic or behavioral factors.

When patients leave the waiting room of their provider, their concerns can go with them. With the help of social media channels like Facebook and Twitter, those concerns can be addressed while information is shared in a new and effective manner.

A research team from the University of Delaware sought to see how much strength one would need, how fast they needed to walk, and how far they needed to walk to achieve a sufficient 6,000 steps in a day, and found that most knee OA patients surpassed their thresholds.

Hurricane Katrina devastated New Orleans 11 years ago. A physician and colleagues documented "Post Katrina Stress Disorder" tells how he came to do the study, and what the disaster was like for him.

If statins are good and PCSK9 inhibitors are better, how good will a combination be? Researchers reported today in a study called GLAGOV.

With more than 10,000 providers from around the world converging on the American Heart Association's Scientific Sessions, lessons from the event can be implemented as soon as the next day or show promise of work to come in the future.

The treatment of cardiovascular disease for men may be ahead of where it is for women, but there is a concerted effort to bring the two into a more balanced measure.

A lot is yet to be determined about the potential benefits of precision medicine in cardiology. As that field develops, there will also be questions about the varying benefits for men and women.

With extensive literature review and expert input, the ACR and the American Association of Hip and Knee Surgeons (AAHKS) have come together to propose a set of guidelines for medication during the perioperative period for patients undergoing knee or hip arthroplasty.

A PCSK9 inhibitor that reduces cholesterol by RNA interference instead of the monoclonal antibody approach appears effective and holds the promise of fewer injections and lower cost, researchers said today.

Praluent has been studied at a variety of levels and, now that it's been approved, there has been more insight on its benefits and risks.

With statins being a common treatment option to help patients reduce their cholesterol levels, the still relatively newly approved PCSK9 inhibitors have proven a valuable tool. However, they are not enough to help eliminate concerns about cardiac care and cholesterol.

Doctors prescribing Praluent for their patients have two dosing options to choose from. Studies on the treatment option have shown that the safety profile for both are good for patients.

In just over a year, Praluent has shown benefits in helping patients lower their cholesterol level. Despite the progress, there have also been some challenges.

Researchers who evaluated adverse events in a large sample of patients taking NSAIDs for arthritis came to a surprising conclusion: celecoxib is the safest of three drugs studied.

Left ventricular assist devices are usually associated with keeping patients alive while they wait for a heart transplant. Using the devices with aggressive drug therapy enabled some patients to recover heart function and forgo the pumps.

One of the biggest challenges cardiologists face is treating patients with atrial fibrillation who are undergoing percutaneous coronary intervention, particularly when it comes to prescribing anticoagulants.

Used for treatment of inflammation in rheumatic diseases, glucocorticoids are known to cause osteoporosis. The American College of Rheumatology has put forth new recommendations to hopefully decrease the frequency of bone fractures.

Prescribing rheumatologists discussed drug interactions, costs, contraindications, and severity of side effects with less than 50% of the patients in the study to whom they had prescribed disease-modifying antirheumatic drugs.

An analysis of thousands of patients in Germany taken from a national registry found interventional procedures more dangerous than surgery for severe symptomatic aortic valve stenosis. But there may have been confounding factors.

With ever-growing data that the inflammation in rheumatic conditions can go hand-in-hand with cardiovascular inflammation, two different studies seek to broaden rheumatology’s approach to dangerous conditions it may influence.

Nancy Lane, MD, shared a rheumatologist's perspective in treating patients who suffer pain and osteoporosis.

For doctors concerned about cardiovascular disease in patients, there have been some lingering questions about the best medications to prescribe.

A study comparing whether certain heart patients did better with bilateral arterial grafts than single grafts had the surprising result of finding no benefit at five years.

Nancy Lane, MD, discussed her team's study on abaloparatide, a new preparation of a hormone, and how it can stimulate bone formation.

Speaking at ACR 2016, the current chair of the Spondyloarthritis Research and Treatment Network (SPARTAN) presented data that showed that a combination of inflammatory drugs may inhibit ankylosis, the painful fusion of bones.

According to Lori Fitzpatrick, MD, additional findings showed that regardless of age, whether or not patients have had vertebral or non-vertebral fractures, treatment with abaloparatide worked.